
Australians diagnosed with a rare form of lung cancer can now access the life-saving drug Retevmo for just $30 per script, down from $10,000 a month.
This change comes after the drug was added to the Pharmaceutical Benefits Scheme (PBS).
For Ian Hill, a Melbourne father of two, Retevmo provided life-changing results after he was diagnosed with Stage 4 lung cancer.
Following chemotherapy, which left him bedridden, genetic testing revealed he had a rare mutation, making him eligible for the drug.
Before it was listed on the PBS, Retevmo could cost up to $200,000, but now it will be available to patients for a fraction of the price.
Health Minister Mark Butler estimates that about 130 patients will benefit annually.
For Ian, the drug has effectively stopped the cancer, allowing him to spend more time with his family without the financial burden.
Medical oncologist Dr. Tom John emphasized the importance of making the treatment accessible to all, regardless of financial status.